We showed that, consistent with our preclinical studies, SVECs from humans with type 2 diabetes and advanced atherosclerosis have blunted serine phosphorylation of eNOS in response to both insulin and IGF-1. This evidence concerns the gene INS and type 2 diabetes mellitus.